Abstract
Cell and gene therapies (CGTs) is a rapidly growing therapeutic area holding great promise for treating rare diseases with high unmet medical needs, with nearly 60% of the 2,400 ongoing CGT trials at the end of 2021 targeting prevalent diseases. Our paper aims to highlight, among the markets in scope, where recent policy developments suggest the most promising or challenging outlook.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
